Merck and its German cousin spar over branding; Turing kicks off ketamine trial;

@FierceBiotech: Johns Hopkins flags another possible successor to 'Special K' for depression. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Did I say the eteplirsen data was messy? More from the FDA (PDF) | Follow @JohnCFierce

@DamianFierce: $MRK is mad about Merck, KGaA, Darmstadt, Germany, Earth's rebrand. More (PDF) | Follow @DamianFierce

> Merck KGaA's recent branding overhaul is leading to confusion in the U.S., according to Merck ($MRK), which filed a lawsuit challenging its distant relative's marketing practices. More

> Turing Pharmaceuticals, under new management after founder Martin Shkreli's arrest, has begun clinical trials on an intranasal formulation of ketamine designed to treat suicidal thoughts. News

> Pfizer ($PFE) signed a deal with the nonprofit California Institute for Biomedical Research to work together on antibody treatments for heart failure. Item

Medical Device News

@FierceMedDev: FDA makes increasing use of 'real-world' device data a strategic priority. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Heartware shares plunge on bad new about device trial. Article | Follow @VarunSaxena2

@EmilyWFierce: NIH urged to 'break taboo' against using its power to bypass drug patents. FiercePharma article | Follow @EmilyWFierce

> JPM: St. Jude plagued by gap in its portfolio of pacemakers and implantable defibrillators. Story

> NIH commits $313M over four years to sequencing genomics of human disease. Article

> Devices grab $2.7B in VC again, but that may weaken in 2016. Editor's corner

Pharma News

@FiercePharma: Dechra's growth spurt continues with $6M acquisition of Mexican manufacturer. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Huge consumer med capacity coming online for Bayer in China as the economy tanks. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: $GSK vaccines head Slaoui says the company's vax and pharma businesses need each other--aka, no break-up, please | Follow @CarlyHFierce

> It's Merck vs. Merck as name cofusion, complicated by social media, leads to legal showdown. More

> Akorn estimates it overstated '14 financials by $35M. Item

> Merck reaches $830M settlement in long-running Vioxx litigation. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.